Clinical trials: GFAP
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis, NMO Spectrum Disorder
China National Registry of Neuro-Inflammatory Diseases
Central nervous system (CNS) idiopathic inflammatory demyelinating diseases (IDD) are mainly diseases caused by autoimmune factors that result in CNS demyelination damage and loss.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases
- Trial name
- CNRID (NCT05154370)
- Testing
- Intravenous steroid
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Beijing Tiantan Hospital
Traumatic Brain Injury
The Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT)
There are no therapeutic agents that have been shown to improve outcomes from severe traumatic brain injury (TBI). Critical barriers to progress in developing treatments for severe TBI are the lack of: 1) monitoring biomarkers…
- Trial name
- NCT04855396
- Where
- 11 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Pediatric Traumatic Brain Injury
Validating a Blood Test for the Detection of Traumatic Brain Injury in Children
The primary objective of this study is to establish if Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) are predictive of computed tomography (CT) findings in pediatric traumatic brain…
- Trial name
- NCT06940232
- Testing
- Blood Test for Glial Fibrillary Acidic Protein (GFAP) and Ubiquitin C-terminal Hydrolase L1 (UCH-L1) Acute Biomarkers
- Where
- United States
- Volunteers
- 330 people
- Sponsor
- University of Nebraska
Congenital Heart Disease (CHD), Hypoxic Encephalopathy
Early Detection of Brain Injury After Congenital Heart Surgery in Infants
Infants with congenital heart disease undergoing cardiac surgery with extracorporeal circulation are at risk for perioperative hypoxic-ischaemic brain injury.
- Trial name
- NCT07424976
- Testing
- Observational study: blood analisys, EEG, MRI
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Dexmedetomidine
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia
Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in…
- Trial name
- NCT03234660
- Testing
- Dexmedetomidine Hydrochloride, control
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Multiple Sclerosis
Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease.
- Trial name
- NeurofilMS (NCT03981003)
- Testing
- Blood sample
- Where
- 28 sites in France, Martinique
- Volunteers
- 1,150 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Stroke Code, Large Vessel Occlusion
Evaluation of a Point-of-care Lateral Flow Assay in Glial Fibrillary Acidic Protein (GFAP) and D-dimer in Diagnosis of Large Vessel Occlusion Acute Ischemic Stroke in a Pediatric Hospital
The goal of this study is to test the efficacy of a rapid bedside blood test in determining if a stroke is happening in children who present to the emergency department with stroke symptoms.
- Conditions
- Stroke Code, Large Vessel Occlusion, Acute Ischemic Stroke
- Trial name
- NCT07474675
- Testing
- Point of Care Rapid Assay
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Boston Children's Hospital
Premature Birth, Brain Injuries
S100B as a Marker of Brain Injury of Preterm Infants
The improvement of treatment of preterm neonates improved their survival, however there is still significant portion of preterm infants (specifically very preterm infants) that suffers from brain insults and as a result…
- Conditions
- Premature Birth, Brain Injuries, Leukomalacia Periventricular, Developmental Disabilities
- Trial name
- PTS100B (NCT02082535)
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Autoimmune GFAP Astrocytopathy
GFAP Auto-immunity : a French Cohort Study
Glial fibrillary acidic protein (GFAP)-Immunoglobulin G (IgG) have recently been described as a biomarker of a novel inflammatory central nervous system (CNS) disorder, termed autoimmune GFAP astrocytopathy.
- Trial name
- GFAP (NCT04463550)
- Testing
- Description and analysis
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Hospices Civils de Lyon
Cardiac Surgery Requiring Cardiopulmonary Bypass, Brain Injury
The Association Between Tau & GFAP and Postoperative Neurological Impairment in Patients Undergoing Cardiac Surgery
Patients born with heart defects often undergo surgical procedures on a heart lung machine. With improvements in medical and surgical management, their survival has significantly improved, but their brain insult has not been paid…
- Conditions
- Cardiac Surgery Requiring Cardiopulmonary Bypass, Brain Injury, Congenital Heart Defect
- Trial name
- NCT06899971
- Testing
- Collecting discarded blood samples
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Boston Children's Hospital
Multiple Sclerosis
Validation of Ella Platform for Serum Nfl And GFAP Measures In Multiple Sclerosis Patients
Serum neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) measured by single molecule array (SIMOA) are novel biomarkers of multiple sclerosis patients (MS) activity and progression.
- Trial name
- Nf-Ella Loca (NCT05352971)
- Testing
- Biomarker quantification
- Where
- 10 sites in France
- Volunteers
- 664 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes